CVCarrie R. Valentine

Carrie R. Valentine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carrie R. Valentine has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Jessica L. Raney

    Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079, USA

    2 shared publications
  • Robert R. Delongchamp

    Division of Biometry and Risk Assessment, National Center for Toxicological Research, Jefferson, Arkansas

    2 shared publications
  • Bentley A. Fane

    Department of Veterinary Sciences and Microbiology, University of Arizona, Tucson, Arizona

    1 shared publication
  • Beverly A. Montgomery

    Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas

    1 shared publication
  • Heinrich V. Malling

    National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina

    1 shared publication
  • Heinrich V. Malling

    Mammalian Mutagenesis Group, Laboratory of Toxicology, Environmental Toxicology Program, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709-2233, USA

    1 shared publication

Latest Publications

  • In vivo mutation in gene A of splenic lymphocytes from ΦX174 transgenic mice

    by Carrie R. Valentine, Jessica L. Raney, Joseph G. Shaddock, Vasily N. Dobrovolsky, Robert R. Delongchamp

    Single‐burst analysis was applied to a forward assay for gene A mutation in splenic lymphocytes of ΦX174 transgenic mice for the purpose of optimizing analytical parameters for identifying in vivo mutations. The effect of varying the cutoff value for an in vivo burst on induced mutant frequency, fold increase, and the significance of the difference between control and N‐ethyl‐N‐nitrosourea (ENU)‐treated mice was calculated by two different methods. The plating density was reduced to an average of less than 10 background mutant plaques per aliquot in order to separate in vitro bursts. The spectrum of mutations contributing < 60 plaques per aliquot from control animals was not significantly different from the control spectra from E. coli or transgenic ΦX174 cells in culture. The mutant spectra from ENU‐treated animals was highly different between mutant bursts of > 80 plaques per aliquot compared to mutations contributing < 60 plaques per aliquot (P < 0.000001), the former fitting the spectrum expected for ENU‐induced mutations. The latter spectrum was also different from control animals and E. coli (P < 0.000001), suggesting the difference was caused by ex vivo mutation. With the mutations found in this study, the total number of reported target sites for gene A is now 33. The results support the interpretation that, in contrast to results for the lacI transgene, 100% of mutants isolated in gene A from control animals and cells were fixed in E. coli. We attribute the difference between the two genes to hot‐spot sites for mutation in gene A and to a testable hypothesis that the mosaic plaque assay for the lacI transgene underestimates the frequency of ex vivo mutants. Environ. Mol. Mutagen. 44:128–150, 2004. Published 2004 Wiley‐Liss, Inc.


  • Spontaneous mutant frequency and mutation spectrum for gene A of ΦX174 grown in E. coli

    by Jessica L. Raney, Robert R. Delongchamp, Carrie R. Valentine

    The use of transgenic targets for measuring mutant frequencies in mammalian tissue requires an estimate of the mutant frequency that results from recovery of the transgene in bacterial recovery systems. In this study, we have determined the spontaneous mutant frequency, estimated the mutation rate, and ascertained the mutation spectrum for gene A of ΦX174 grown in E. coli strain CQ2 from 156 small independent cultures. The mutant frequency of 12 of the 156 cultures was 17 ± 1.0 × 10−6 and the estimated mutation rate per gene replication was 7.4 ± 2.3 × 10−6. The mutant frequency and spectrum from E. coli were not significantly different from that of solvent-treated embryonic mouse cells in culture, 19 ± 0.5 × 10−6 (Valentine CR et al. [2002]: Environ Mol Mutagen 39:55–68), indicating that those spontaneous mutants were primarily derived from E. coli. The E. coli spectrum was heavily weighted toward two major target sites (hot spots), 4225A→G (56%) and 4218G→A or C (20%). Four new target sites and one new mutational event were recovered by the gene A forward assay. A mutant spectrum from an expanded phage stock was also determined to assess the effects of propagating the virus. This mutant frequency was higher (6 × 10−4), contained more double mutants (15% compared to 0.6%), and had a significantly different spectrum from the spectrum for independent cultures (fewer A:T→G:C and G:C→C:G changes and more G:C→A:T; P < 0.002). The E. coli mutation spectrum will be useful for determining the origin of gene A mutation in tissues of ΦX174 transgenic mice. Environ. Mol. Mutagen. 44:119–127, 2004. Published 2004 Wiley-Liss, Inc.


  • Characterization of mutant spectra generated by a forward mutational assay for gene A of ΦX174 from ENU‐treated transgenic mouse embryonic cell line PX‐2†

    by Carrie R. Valentine, Beverly A. Montgomery, Scott G. Miller, Robert R. Delongchamp, Bentley A. Fane, Heinrich V. Malling

    The sensitivity of in vivo transgenic mutation assays benefits from the sequencing of mutations, although the large number of possible mutations hinders high throughput sequencing. A forward mutational assay exists for ΦX174 that requires an altered, functional ΦX174 protein and therefore should have fewer targets (sense, base‐pair substitutions) than forward assays that inactivate a protein. We investigated this assay to determine the number of targets and their suitability for detecting a known mutagen, N‐ethyl‐N‐nitrosourea (ENU). We identified 25 target sites and 33 different mutations in ΦX174 gene A after sequencing over 350 spontaneous and ENU‐induced mutants, mostly from mouse embryonic cell line PX‐2 isolated from mice transgenic for ΦX174 am3,cs70 (line 54). All six types of base‐pair substitution were represented among both the spontaneous and ENU‐treated mutant spectra. The mutant spectra from cells treated with 200 and 400 μg/ml ENU were both highly different from the spontaneous spectrum (P < 0.000001) but not from each other. The dose trend was significant (P < 0.0001) for a linear regression of mutant frequencies (R2 = 0.79), with a ninefold increase in mutant frequency at the 400 μg/ml dose. The spontaneous mutant frequency was 1.9 × 10−5 and the spontaneous spectrum occurred at 11 target base pairs with 15 different mutations. Thirteen mutations at 12 targets were identified only from ENU‐treated cells. Seven mutations had highly significant increases with ENU treatment (P < 0.0001) and 15 showed significant increases. The results suggest that the ΦX174 forward assay might be developed into a sensitive, inexpensive in vivo mutagenicity assay. Environ. Mol. Mutagen. 39:55–68, 2002 Published 2002 Wiley‐Liss, Inc.


    • 1 January 2001
      • Vol. 37  (4) , 356-60

    Estimation of the average burst size of Phix174 am3, cs70 for use in mutation assays with transgenic mice.

    by R R Delongchamp, C R Valentine, H V Malling

    In mutation assays using transgenic mice, with recoverable vectors such as PhiX174 am3, cs70, mutations originate from two sources: (1) in vivo mutations, that is, mutations that were fixed in the mouse, or (2) ex vivo mutations, that is, mutations that were fixed during recovery or plating. When a bacteriophage infects a bacterium, it multiplies and bursts the cell, releasing a number of phages referred to as the burst size. Our method for distinguishing between in vivo mutations and ex vivo mutations estimates the average number of bursts, the denominator of in vivo mutant frequencies, by dividing the total plaque-forming units (PFU) by the average number of phages in a burst. Herein, we outline a probability model relating observed plaque counts to the burst size and present the statistical method used to estimate the burst size. The average size of a single burst from nonrevertant phages was estimated in eight studies under the conditions of our mutation assay. The average burst size was stable across studies at 182.5 plaques per burst (standard error, 14.25). The probability that a burst is a specific size was approximated by a negative binomial distribution, which implies a Poisson-Pascal distribution for the observed plaque counts. The observed plaque counts were adequately fit by this approximation. Environ. Mol. Mutagen. 37:356-360, 2001 Published 2001 Wiley-Liss, Inc.

    • 1 June 1997
      • Vol. 3  (6) , 660-76

    The association of nonsense mutation with exon-skipping in hprt mRNA of Chinese hamster ovary cells results from an artifact of RT-PCR.

    by C R Valentine, R H Heflich

    RT-PCR of RNA from CHO cells with nonsense mutations in the hprt gene frequently detects minor hprt mRNA species lacking one or more exons. Many nonsense mutants also contain greatly reduced concentrations of the major, normally spliced hprt mRNA. In this study, we examined the hypothesis that exon-deleted mRNAs are normal constituents of CHO cells, but are not detected in wild-type parental cells and most missense mutants because their amplification is suppressed by relatively high concentrations of normally spliced hprt mRNA. A protocol designed to specifically detect exon-deleted mRNAs was conducted using RNA from parental cells and identified all the exon-deleted species typical of nonsense mutants. Quantitative analysis of parental cell RNA measured these exon-deleted mRNAs at < or = 0.7% of the abundance of the full-sized species. Nonsense and missense mutants had comparable amounts of exon-deleted mRNAs, which varied both above and below parental concentrations. The relative concentrations of particular exon-deleted species could be explained by the location of nonsense mutations remaining in the mRNA or by structural effects of mutations on splicing. Exon-deleted mRNAs were detected by RT-PCR when the concentration of the most abundant exon-deleted species was > or = 2% of the full-length mRNA. This occurred for mutants with nonsense mutations in internal exons. RT-PCR conditions were shown to suppress the amplification of exon-deleted species 40-fold when full-length mRNA was abundant, which occurred for parental lines and missense mutants. Our results verify that RT-PCR conditions can produce an artifactual association between nonsense mutation and exon-skipping when minor, exon-deleted mRNA is relatively enriched.